Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group B Streptococcus conjugate vaccine (Biovac)
- Development stage
- Preclinical
- Lead developer
- Biovac
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Group B Streptococcus (GBS) conjugate vaccine is a pentavalent vaccine candidate being developed by the Biovac Institute in South Africa. It targets five major GBS serotypes—Ia, Ib, II, III, and V—which are responsible for the majority of invasive GBS disease cases globally. The vaccine is constructed by covalently linking the capsular polysaccharides of these serotypes to a tetanus toxoid carrier protein, a design intended to induce a T-cell dependent immune response. This approach is specifically aimed at maternal immunization, where the resulting antibodies are transferred across the placenta to provide passive protection to newborns and young infants against invasive GBS disease. Currently in preclinical development, the vaccine is formulated with aluminum phosphate as an adjuvant and is supported by partnerships with PATH and the Bill & Melinda Gates Foundation.
- Other names
- GBS conjugate vaccinePentavalent GBS conjugate vaccineGroup B Streptococcus polysaccharide-conjugate vaccine
02
Targets
GBS CPS (Group B Streptococcus capsular polysaccharide)
Beyond the preview
Go deeper on Group B Streptococcus conjugate vaccine (Biovac).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group B Streptococcus conjugate vaccine (Biovac).